TWC
BEAM icon

TD Waterhouse Canada’s Beam Therapeutics BEAM Stock Holding History

TD Waterhouse Canada’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed -$4.79K – 1704
2022
Q3 		$4.79K Buy
+100
New +$5.71K ﹤0.01% 1364

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

TD Waterhouse Canada's BEAM Position: Q4 2022 in Review

TD Waterhouse Canada sold out of Beam Therapeutics (BEAM) in Q4 2022, closing a stake of 100 shares — an estimated $4.79K sold.

TD Waterhouse Canada first reported a position in BEAM in Q3 2022 and held it in 1 quarter. The position peaked at $4.79K in Q3 2022. 209 funds tracked by Wall St. Rank hold BEAM as of Q4 2022.

  • TD Waterhouse Canada reported no remaining Beam Therapeutics position as of Q4 2022 after selling out during the quarter.
  • TD Waterhouse Canada sold 100 Beam Therapeutics shares in Q4 2022, an estimated $4.79K.
  • TD Waterhouse Canada first reported a position in Beam Therapeutics in Q3 2022 and held it in 1 quarter.
  • TD Waterhouse Canada's Beam Therapeutics position peaked at $4.79K in Q3 2022.
  • 209 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2022.

Based on TD Waterhouse Canada's 13F filing for Q4 2022, filed 13 Nov 2023.